


SCHEMA

RP2: Cediranib/olaparib vs. cediranib vs. olaparib vs. physician's choice standard chemo -> drop inactive arm(s) to Ph III



Phase II accrual was suspended on June 16, 2017. At the interim analysis in July 2018, the Data Monitoring Committee voted to drop the single-agent olaparib arm. The Phase III trial will be continued with 3 arms: standard chemotherapy, cediranib+olaparib, and cediranib alone. Phase II patients treated on these three arms will be included in the Phase III trial. References to the single-agent olaparib arm have been retained in the protocol for context.